# US 2019/0314334 A1 · Compounds for the treatment of autoimmune diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314334 A1
- Document ID: US20190314334A1
- Status: Published application
- Kind: A1
- Application number: 16/347,845
- Filed: 2017-11-07
- Published: 2019-10-17
- Earliest claimed: 2016-11-08
- Assignees: Quimatryx, S.L.
- Applicants: Quimatryx, S.L.
- Inventors: Yosu Ion VARA SALAZAR; Eneko ALDABA ARÉVALO; Ferdinando NICOLETTI; Massimo LIBRA; Katia Domenica MANGANO
- Web page: https://patentgrep.com/patent/US20190314334A1

## CPC

- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/402: 1-aryl substituted, e.g. piretanide
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention refers to the use of compounds derived from trisubstituted 1H-pyrrole rings and aromatic rings, which have the following formula (I): wherein R1 and R2 represent, independently of each other: an optionally substituted phenyl ring, or an optionally substituted 5-membered heteroaromatic ring; one of R3 and R4 is H and the other represents a group wherein W is OH or an ortho-aniline group; each A, independently of each other, represents a —CH2— group or is absent; ═Y—Y═ is ═HC—CH═, ═N—CH═, or ═HC—N═; or a salt or solvate thereof, in the prevention or treatment of an autoimmune disease.

## Claims

### Claim 1

A method for the prevention or treatment of multiple sclerosis, acute-disseminated encephalomyelitis or autoimmune hepatitis, said method comprises the administration to a patient in need of such treatment of a therapeutically effective amount of a compound of general formula (I)
wherein
R1 and R2 represent, independently of each other:
an optionally substituted phenyl ring, or
an optionally substituted 5-membered heteroaromatic ring;
one of R3 and R4 is H and the other represents a
group wherein W is OH or an ortho-aniline group;
each A, independently of each other, represents a —CH2— group or is absent;
═Y—Y═ is ═HC—CH═, ═N—CH═, or ═HC—N═;
or a salt or solvate thereof.

### Claim 2 (depends on 1)

The method according to claim 1, which is a compound of general formula (II):
wherein
R1 and R2 are as defined in claim 1;
═Y— is ═CH— or ═N—;
or a salt or solvate thereof.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the optionally substituted phenyl ring is a non-substituted phenyl ring or a phenyl ring substituted with OH, OR5, or halogen, wherein R5 is a C1-C6 alkyl group.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the optionally substituted 5-membered heteroaromatic ring is a non-substituted furan, a non-substituted thiophene or a non-substituted pyrrole ring.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the compound of formula (I) is selected from the following list:
or a salt or solvate thereof.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the compound of formula (I) is selected from the following list:
or a salt or solvate thereof.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the compound of formula (I) is
or a salt or solvate thereof.

### Claim 8 (depends on 1)

The method according to claim 1, which wherein the compound of formula (I) is

### Claim 9 (depends on 1)

The method according to claim 1, for the prevention or treatment of multiple sclerosis.

### Claim 10 (depends on 1)

The method according to claim 1, for the prevention or treatment of acute-disseminated encephalomyelitis.

### Claim 11 (depends on 1)

The method according to claim 1, for the prevention or treatment of autoimmune hepatitis.
